AR036180A1 - Formulacion liofilizada que comprende 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina, su uso para la fabricacion de un medicamento, articulo de fabricacion que la comprende y proceso para prepararla - Google Patents
Formulacion liofilizada que comprende 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina, su uso para la fabricacion de un medicamento, articulo de fabricacion que la comprende y proceso para prepararlaInfo
- Publication number
- AR036180A1 AR036180A1 ARP020102700A ARP020102700A AR036180A1 AR 036180 A1 AR036180 A1 AR 036180A1 AR P020102700 A ARP020102700 A AR P020102700A AR P020102700 A ARP020102700 A AR P020102700A AR 036180 A1 AR036180 A1 AR 036180A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- methyl
- olanzapine
- manufacture
- solubilizer
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 5
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 5
- 229960005017 olanzapine Drugs 0.000 abstract 4
- 230000005284 excitation Effects 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000005022 packaging material Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30682901P | 2001-07-20 | 2001-07-20 | |
| US38647402P | 2002-06-07 | 2002-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036180A1 true AR036180A1 (es) | 2004-08-18 |
Family
ID=26975390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102700A AR036180A1 (es) | 2001-07-20 | 2002-07-18 | Formulacion liofilizada que comprende 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina, su uso para la fabricacion de un medicamento, articulo de fabricacion que la comprende y proceso para prepararla |
Country Status (32)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7323459B2 (en) * | 2002-12-24 | 2008-01-29 | Teva Pharmaceutical Industries Ltd. | Crystal forms, methods for their preparation and method for preparation of olanzapine |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
| ATE504588T1 (de) | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| WO2006076124A2 (en) * | 2004-12-16 | 2006-07-20 | Nektar Therapeutics | Stable, non-crystalline formulation comprising olanzapine |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
| EP3735223A4 (en) * | 2018-01-05 | 2021-10-13 | Impel Neuropharma Inc. | INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE |
| PE20212195A1 (es) * | 2019-03-01 | 2021-11-15 | Eurofarma Laboratorios S A | Composicion farmaceutica liofilizada de antiinflamatorio no esteroideo |
| HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
| CN115006406A (zh) * | 2021-12-28 | 2022-09-06 | 南京清普生物科技有限公司 | 一种稳定的奥氮平制剂 |
| WO2025056094A1 (zh) * | 2023-09-15 | 2025-03-20 | 广州帝奇医药技术有限公司 | 一种冻干制剂和注射液及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0421297T3 (da) * | 1989-09-30 | 1994-01-17 | Eisai Co Ltd | Injicerbare præparater indeholdende cephalosporin som lægemiddel og anvendelse deraf |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
2002
- 2002-05-07 UA UA2004010428A patent/UA80095C2/uk unknown
- 2002-07-05 WO PCT/US2002/019799 patent/WO2003007912A2/en not_active Ceased
- 2002-07-05 EA EA200400211A patent/EA006506B1/ru not_active IP Right Cessation
- 2002-07-05 SI SI200230629T patent/SI1423124T1/sl unknown
- 2002-07-05 EP EP02749634A patent/EP1423124B1/en not_active Expired - Lifetime
- 2002-07-05 BR BR0211250-7A patent/BR0211250A/pt not_active IP Right Cessation
- 2002-07-05 PT PT02749634T patent/PT1423124E/pt unknown
- 2002-07-05 DE DE60221674T patent/DE60221674T2/de not_active Expired - Lifetime
- 2002-07-05 AU AU2002320134A patent/AU2002320134B2/en not_active Expired
- 2002-07-05 KR KR10-2004-7000829A patent/KR20040017330A/ko not_active Ceased
- 2002-07-05 PL PL02366614A patent/PL366614A1/xx not_active Application Discontinuation
- 2002-07-05 CZ CZ200484A patent/CZ200484A3/cs unknown
- 2002-07-05 CA CA002448724A patent/CA2448724A1/en not_active Abandoned
- 2002-07-05 IL IL15909802A patent/IL159098A0/xx unknown
- 2002-07-05 SK SK18-2004A patent/SK182004A3/sk unknown
- 2002-07-05 AT AT02749634T patent/ATE369137T1/de active
- 2002-07-05 JP JP2003513521A patent/JP2004537546A/ja active Pending
- 2002-07-05 ES ES02749634T patent/ES2289126T3/es not_active Expired - Lifetime
- 2002-07-05 US US10/480,617 patent/US20040176357A1/en not_active Abandoned
- 2002-07-05 DK DK02749634T patent/DK1423124T3/da active
- 2002-07-05 MX MXPA04000541A patent/MXPA04000541A/es active IP Right Grant
- 2002-07-05 NZ NZ529667A patent/NZ529667A/en not_active IP Right Cessation
- 2002-07-05 HU HU0401157A patent/HUP0401157A3/hu unknown
- 2002-07-05 HR HR20040037A patent/HRP20040037A2/hr not_active Application Discontinuation
- 2002-07-05 CN CNA028144473A patent/CN1537007A/zh active Pending
- 2002-07-17 PE PE2002000636A patent/PE20030281A1/es active IP Right Grant
- 2002-07-18 MY MYPI20022723A patent/MY135452A/en unknown
- 2002-07-18 AR ARP020102700A patent/AR036180A1/es not_active Application Discontinuation
- 2002-07-19 SV SV2002001179A patent/SV2003001179A/es not_active Application Discontinuation
-
2003
- 2003-12-31 CO CO03113784A patent/CO5540279A2/es not_active Application Discontinuation
-
2004
- 2004-01-30 ZA ZA2004/00798A patent/ZA200400798B/en unknown
-
2007
- 2007-10-11 CY CY20071101308T patent/CY1107759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ503641A (en) | Sustained release formulation of olanzapine pamoate suitable for treating psychotic patients | |
| AR010448A1 (es) | PROCEDIMIENTO PARA OBTENER LA FORMA II POLIMORFA DE 2-METIL-4-[4-METIL-1- PIPERACINIL]-10H-TIENO-[2,3-b]-[1,5]-BENZODIACEPINA (OLANZAPINA) | |
| MX173791B (es) | Procedimiento para la produccion de 2-metil-10(4-metil 1-piperazinil)-4h-tieno[2,3-b][1,5] benzodiazepina y producto obtenido | |
| HUP0000065A2 (hu) | Olanzapin-dihidrát D és az azt tartalmazó gyógyszerkészítmények | |
| KR960000229A (ko) | 티에 노［1, 5］벤조디아제 핀의 용도 | |
| NZ541014A (en) | Use of N-desmethylclozapine to treat schizophrenia while increasing the level of activity of a muscarinic receptor | |
| BR9807223A (pt) | Processo de moldagem de injeção e aparelho para produzir artigos a partir de dois componentes | |
| MX9603669A (es) | Proceso de mezcla para la preparacion de fibrilas biodegradables, materiales no tejidos que comprenden fibrilas biodegradables y productos que comprenden dichos materiales no tejidos. | |
| MX9603668A (es) | Procesos de rociado que utilizan un flujo gaseoso para preparar fibrilas biodegradables, materiales no tejidos que comprenden fibrilas biodegradables y articulos que comprenden dichos materiales no tejidos. | |
| CY1105319T1 (el) | Ταχεως αποσαθρουμενη απο του στοματος συνταγοποιηση του valdecoxib | |
| ATE500258T1 (de) | Verfahren zur herstellung von olanzapin form i | |
| BR9808077A (pt) | Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente | |
| ES2131318T3 (es) | Pelets. | |
| BR0014826A (pt) | Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| HUP0301082A2 (hu) | Új polimorf olanzapine hidroklorid sók, eljárás ezek előállítására, az ezeket tartalmazó gyógyászati készítmények és felhasználásuk | |
| PE20030281A1 (es) | Formulacion liofilizada de 2-metil-tieno-benzodiazepina | |
| ATE302681T1 (de) | Verfahren und vorrichtung zur herstellung einer pet flasche mit aussermittigem flaschenhals | |
| AU2002320134A1 (en) | Lyophilized formulation comprising olanzapine | |
| ES2132819T3 (es) | Maquina y procedimiento para producir recipientes de material termoplastico en una sola fase. | |
| DE2964557D1 (en) | 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thiophen-4,9 imines, process for their preparation and pharmaceutical compositions containing them | |
| BR9812820A (pt) | Concentração de absorção de lìquido no centro de artigos absorventes respiráveis | |
| HUP9902882A2 (hu) | Olanzapin alkalmazása álmatlanság kezelésére szolgáló gyógyszerkészítmények előállítására | |
| Peh et al. | Psychiatric complications of Erimin abuse | |
| Kujawa et al. | Switching to aripiprazole monotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |